Holdings of Commodore Capital LP
30 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 68.7 % of the equity sleeve
Sector breakdown
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|
| 1 | US | 30 | 1.4B $ | 100.00 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|
| 1 | Relay Therapeutics Inc | 17,000,000 | 169.2M $ | |
| 2 | Enliven Therapeutics Inc | 3,275,000 | 128.4M $ | |
| 3 | Cogent Biosciences Inc | 2,888,007 | 111.2M $ | |
| 4 | Spyre Therapeutics Inc | 1,912,380 | 96.5M $ | |
| 5 | Tyra Biosciences Inc | 2,475,000 | 94.8M $ | |
| 6 | Celldex Therapeutics Inc | 2,696,616 | 85.5M $ | |
| 7 | Nuvalent Inc | 833,600 | 85.4M $ | |
| 8 | Amylyx Pharmaceuticals Inc | 5,650,000 | 78.5M $ | |
| 9 | Kymera Therapeutics Inc | 750,000 | 62.5M $ | |
| 10 | Alto Neuroscience Inc | 2,723,196 | 61.2M $ | |
| 11 | Erasca Inc | 3,175,000 | 51.4M $ | |
| 12 | DAMORA THERAPEUTICS INC | 1,939,000 | 50.2M $ | |
| 13 | LB Pharmaceuticals Inc | 1,500,000 | 37M $ | |
| 14 | EyePoint Inc | 2,825,000 | 36.4M $ | |
| 15 | Nurix Therapeutics Inc | 2,275,000 | 35.3M $ | |
| 16 | Corvus Pharmaceuticals Inc | 2,258,735 | 33M $ | |
| 17 | Assembly Biosciences Inc | 1,000,000 | 27.8M $ | |
| 18 | Perspective Therapeutics Inc | 6,336,782 | 26.4M $ | |
| 19 | Soleno Therapeutics Inc | 652,432 | 21.8M $ | |
| 20 | Ocular Therapeutix Inc | 2,575,000 | 21.8M $ | |
| 21 | Century Therapeutics Inc | 8,695,652 | 19.7M $ | |
| 22 | SAB Biotherapeutics Inc | 4,401,500 | 16.9M $ | |
| 23 | Palisade Bio Inc | 7,181,062 | 12.6M $ | |
| 24 | Karyopharm Therapeutics Inc | 1,950,000 | 10.9M $ | |
| 25 | Inhibikase Therapeutics Inc | 5,397,488 | 9.1M $ | |
| 26 | AN2 Therapeutics Inc | 2,333,713 | 8M $ | |
| 27 | PepGen Inc | 4,475,000 | 7.9M $ | |
| 28 | AVALO THERAPEUTICS INC | 483,000 | 7.2M $ | |
| 29 | LeonaBio Inc | 464,398 | 4.8M $ | |
| 30 | Relmada Therapeutics Inc | 633,901 | 4.4M $ | |